| Recommendations—initiating T therapy . | LoE . | Grade . |
|---|---|---|
| Perform CV, prostate, breast, and hematologic assessments before start of treatment | 1a | A |
| Offer T therapy to symptomatic men with TD syndrome for treated localized low-risk prostate cancer (Gleason score < 8, stages 1–2, preoperative PSA level < 10 ng/mL, and not starting before 1 y of follow-up) and without evidence of active disease (based on measurable PSA level, DRE result, and evidence of metastatic disease) | 3 | B |
| Assess CV risk factors before commencing T therapy and optimize secondary prevention in men with established disease | 1a | A |
| Recommendations—initiating T therapy . | LoE . | Grade . |
|---|---|---|
| Perform CV, prostate, breast, and hematologic assessments before start of treatment | 1a | A |
| Offer T therapy to symptomatic men with TD syndrome for treated localized low-risk prostate cancer (Gleason score < 8, stages 1–2, preoperative PSA level < 10 ng/mL, and not starting before 1 y of follow-up) and without evidence of active disease (based on measurable PSA level, DRE result, and evidence of metastatic disease) | 3 | B |
| Assess CV risk factors before commencing T therapy and optimize secondary prevention in men with established disease | 1a | A |
| Recommendations—initiating T therapy . | LoE . | Grade . |
|---|---|---|
| Perform CV, prostate, breast, and hematologic assessments before start of treatment | 1a | A |
| Offer T therapy to symptomatic men with TD syndrome for treated localized low-risk prostate cancer (Gleason score < 8, stages 1–2, preoperative PSA level < 10 ng/mL, and not starting before 1 y of follow-up) and without evidence of active disease (based on measurable PSA level, DRE result, and evidence of metastatic disease) | 3 | B |
| Assess CV risk factors before commencing T therapy and optimize secondary prevention in men with established disease | 1a | A |
| Recommendations—initiating T therapy . | LoE . | Grade . |
|---|---|---|
| Perform CV, prostate, breast, and hematologic assessments before start of treatment | 1a | A |
| Offer T therapy to symptomatic men with TD syndrome for treated localized low-risk prostate cancer (Gleason score < 8, stages 1–2, preoperative PSA level < 10 ng/mL, and not starting before 1 y of follow-up) and without evidence of active disease (based on measurable PSA level, DRE result, and evidence of metastatic disease) | 3 | B |
| Assess CV risk factors before commencing T therapy and optimize secondary prevention in men with established disease | 1a | A |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
